Kinfo
ArriVent BioPharma, Inc. logo

ArriVent BioPharma, Inc.

AVBPNASDAQHealthcare·US · USD
$13.64
+1.41 (+11.53%)
Prices as of November 6, 2026 · market closed

Price

Key statistics

Valuation
Market cap672.56M USD
Enterprise value292.39M USD
Trailing P/E-3.16
Forward P/E-3.34
PEG ratio-0.19
Price / sales0.00
Price / book1.64
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-33.11%
Return on equity-53.25%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA0.00 USD
Net income-164.21M USD
Diluted EPS-$3.62
Rev. growth (YoY)0.00%
Balance sheet
Total cash373.12M USD
Total debt351.00K USD
Debt / equity0.10
Current ratio14.16
Book value / share$7.59
Cash flow (TTM)
Operating cash flow-147.93M USD
Levered free cash flow-89.48M USD
Shares & price
Shares outstanding48.32M
Float29.59M
Held by institutions100.68%
Beta1.66
50-day MA$23.78
200-day MA$26.83
52-week high$35.83
52-week low$11.36
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-12-0.98-1.05−7.14%2026-05-202.913.09+6.19%2026-05-11-0.89-0.96−7.87%2026-03-05-0.85-0.78+8.24%2025-11-10-0.78-0.83−6.41%
About ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat cancers. ArriVent BioPharma, Inc. concentrates on targeted oncology programs designed to address unmet medical needs, with particular emphasis on non-small-cell lung cancer and other solid tumors. Its current portfolio includes development of furmonertinib, an epidermal growth factor receptor mutant-selective therapy being evaluated across multiple EGFR mutation settings, as well as emerging pipeline candidates such as antibody-drug conjugates and other novel therapeutics. The company works through collaborations and in-licensing approaches to advance medicines from discovery into clinical development and, ultimately, patient access. Headquartered in Newtown Square, Pennsylvania, ArriVent BioPharma, Inc. plays a specialized role in the oncology biopharmaceutical market by focusing on precision therapies for genetically defined cancer populations.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Zhengbin Yao Ph.D.
Employees
77
Headquarters
Newtown Square, PA, United States

Frequently asked questions about ArriVent BioPharma, Inc.